Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.

Ascendis Pharma (Nasdaq: ASND) has announced positive top-line data from the pivotal Phase II ApproaCH trial of TransCon CNP ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...

BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be ...

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma ...

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...

In a notable update, Cantor Fitzgerald has reiterated its “Overweight” rating on Ascendis Pharma’s stock. The analyst’s price target remains set at $170, reflecting optimism about the company’s future ...